Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pridopidine - Prilenia Therapeutics

Next Previous
Drug Profile

Pridopidine - Prilenia Therapeutics

Alternative Names: ACR-16; ASP-2314; FR-310826; Huntexil; Nurzigma; TV-7820

Latest Information Update: 16 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroSearch Sweden AB
  • Developer Massachusetts General Hospital; Prilenia Therapeutics; Teva Pharmaceutical Industries
  • Class Antidementias; Antiparkinsonians; Antipsychotics; Eye disorder therapies; Neuropsychotherapeutics; Piperidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor antagonists; Glutamate modulators; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Huntington's disease
  • Phase II/III Amyotrophic lateral sclerosis
  • Phase II Parkinson's disease
  • No development reported Alzheimer's disease; Eye disorders; Fragile X syndrome; Rett syndrome
  • Discontinued Schizophrenia

Most Recent Events

  • 12 Oct 2025 Updated efficacy data from the phase III PROOF-HD trial in Huntington’s Disease released by Prilenia Therapeutics
  • 10 Oct 2025 Prilenia and Ferrer plans a confirmatory trial for Huntington's disease (Early-stage disease) in first half of 2026
  • 06 Oct 2025 Prilenia Therapeutics plans a phase III pivotal trial for Amyotrophic lateral sclerosis in January 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top